Has Nafisa Burhani, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,426,642 in general payments to Nafisa Burhani, MD across 817 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nafisa Burhani, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nafisa Burhani, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nafisa Burhani, MD

Hematology & Oncology · Joliet, ILNPI 1851386460

Payments from drug & device makers

$3,426,642in general payments, 2019–2025

Across 817 payments — averaging $4194.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$2.6M
Genentech, Inc.$177K
Servier Bioinnovation$144K
Merck$142K
Exelixis Inc.$59K
Institut DE Recherches Internationales Servier$53K
plus $226K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	83	$2,625,704
Genentech, Inc.	33	$176,745
Servier Bioinnovation	12	$143,608
Merck	139	$141,686
Exelixis Inc.	19	$59,461
Institut DE Recherches Internationales Servier	12	$53,163
AbbVie	18	$48,068
Eisai Inc.	47	$43,351
Amgen	16	$25,998
F. Hoffmann-la Roche AG	5	$19,683
Helsinn Healthcare SA	3	$15,555
G1 Therapeutics, Inc.	9	$14,750
Acerta Pharma LLC	4	$10,398
Pfizer	29	$8,889
Radius Health, Inc.	2	$7,757
Incyte Corporation	21	$7,175
Pharmacyclics LLC, An Abbvie Company	8	$6,291
Verastem, Inc.	2	$4,647
Beigene USA, Inc.	3	$1,906
Jazz Pharmaceuticals Inc.	7	$1,480
Bristol Myers Squibb	12	$1,432
Athenex Pharmaceutical Division, LLC	1	$1,250
AstraZeneca(2 entities)	40	$861
Institut DE Recherches Servier	3	$697
E.r. Squibb & Sons, L.L.C.	42	$672
Johnson & Johnson(2 entities)	26	$500
Lilly USA, LLC	14	$410
Seagen Inc.	13	$392
Genentech USA, Inc.	21	$388
Daiichi Sankyo Inc.	13	$264
Astellas Pharma US Inc	7	$257
Gilead(2 entities)	14	$242
Sanofi	12	$231
Takeda Pharmaceuticals U.S.A., Inc.	7	$151
Myriad Genetic Laboratories, Inc.	7	$140
GSK	7	$135
Beone Medicines USA, Inc.	5	$124
Array Biopharma Inc	6	$124
EMD Serono, Inc.	5	$113
Agios Pharmaceuticals, Inc.	1	$112
Genmab U.S., Inc.	4	$105
Dendreon Pharmaceuticals LLC	4	$102
Deciphera Pharmaceuticals Inc.	4	$98
Regeneron Healthcare Solutions, Inc.	4	$98
Rigel Pharmaceuticals, Inc.	4	$84
Dova Pharmaceuticals	5	$79
Sobi, Inc	4	$76
Taiho Oncology, Inc.	5	$74
EUSA Pharma (US) LLC	3	$60
Pharmacosmos Therapeutics Inc.	3	$59
Ipsen Biopharmaceuticals, Inc	2	$53
Tesaro, Inc.	2	$52
Mirati Therapeutics, Inc.	2	$49
Servier Pharmaceuticals LLC	2	$47
Karyopharm Therapeutics Inc.	2	$47
Bayer	2	$46
Clovis Oncology, Inc.	3	$43
Invivyd Inc	2	$38
Boehringer Ingelheim	2	$37
ADC Therapeutics America, Inc.	2	$36

How this compares

$3,426,642 in reported general payments places this provider in the 95th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois →

Medicare billing

Part B allowed, 2024

$953,952

Medicare patients

488

Services billed

45,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Joliet

Richard SchilskyBurr Ridge$87.1M
Edwin PosadasBurr Ridge$70.9M
Oana DanciuChicago$23.2M
Shuo MaChicago$20.5M
Olwen HahnChicago$11.9M
Christine BestvinaChicago$11.3M
Russell SzmulewitzChicago$9.8M
Randy SweisChicago$9.4M
Hedy KindlerChicago$8.6M
Reem KarmaliChicago$7.7M

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →